For hepatorenal syndrome with rapid reduction in kidney function. Sold as Terlivaz. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Terlipressin Acetate (sold as Terlivaz), first approved Sep 14, 2022, with 0 new uses approved and 3 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 14, 2022 | TerlivazNDA 22231 · New molecular entity | Mallinckrodt Ireland | 2 | Marketed |
| Feb 18, 2022 | TerlipressinFacility Inspections | Approved |
| Sep 11, 2020 | Terlivaz (terlipressin)Clinical | Approved |
| Nov 4, 2009 | Lucassin (terlipressin)Clinical/Statistical, Product Quality, Labeling | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA